BR9915317A - Método de tratar trombocitopenia induzida por heparina - Google Patents

Método de tratar trombocitopenia induzida por heparina

Info

Publication number
BR9915317A
BR9915317A BR9915317-3A BR9915317A BR9915317A BR 9915317 A BR9915317 A BR 9915317A BR 9915317 A BR9915317 A BR 9915317A BR 9915317 A BR9915317 A BR 9915317A
Authority
BR
Brazil
Prior art keywords
induced thrombocytopenia
heparin
provides
treating heparin
treating
Prior art date
Application number
BR9915317-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Jack Fisher
Betty Sau-Chi Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9915317A publication Critical patent/BR9915317A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR9915317-3A 1998-11-13 1999-11-10 Método de tratar trombocitopenia induzida por heparina BR9915317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10843298P 1998-11-13 1998-11-13
PCT/US1999/026770 WO2000029014A1 (en) 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia

Publications (1)

Publication Number Publication Date
BR9915317A true BR9915317A (pt) 2001-08-07

Family

ID=22322154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915317-3A BR9915317A (pt) 1998-11-13 1999-11-10 Método de tratar trombocitopenia induzida por heparina

Country Status (13)

Country Link
US (1) US6743426B2 (enExample)
EP (1) EP1128842B1 (enExample)
JP (1) JP2002529515A (enExample)
CN (1) CN1326355A (enExample)
AT (1) ATE320263T1 (enExample)
AU (1) AU1477000A (enExample)
BR (1) BR9915317A (enExample)
CA (1) CA2351067A1 (enExample)
DE (1) DE69930419T2 (enExample)
ES (1) ES2259248T3 (enExample)
IL (1) IL142255A0 (enExample)
WO (1) WO2000029014A1 (enExample)
ZA (1) ZA200102722B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
CA2694189A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US9271999B2 (en) 2012-05-09 2016-03-01 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
WO1992011757A1 (en) 1991-01-11 1992-07-23 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA199900862A1 (ru) * 1997-03-24 2000-04-24 Эли Лилли Энд Компани Способ лечения сосудистых нарушений
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
ZA200102722B (en) 2002-05-03
WO2000029014A1 (en) 2000-05-25
EP1128842B1 (en) 2006-03-15
AU1477000A (en) 2000-06-05
DE69930419T2 (de) 2006-09-07
ES2259248T3 (es) 2006-09-16
US6743426B2 (en) 2004-06-01
CN1326355A (zh) 2001-12-12
CA2351067A1 (en) 2000-05-25
ATE320263T1 (de) 2006-04-15
EP1128842A1 (en) 2001-09-05
US20010018050A1 (en) 2001-08-30
JP2002529515A (ja) 2002-09-10
IL142255A0 (en) 2002-03-10
DE69930419D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
PT817627E (pt) Inibidores da proteina cinase c
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
ES2170174T3 (es) Proceso continuo para la preparacion de poliamidas.
ATE234092T1 (de) 2-alkylpyrrolidine
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
IL142220A0 (en) Method of treating viral hemorrhagic fever
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
HK1039449A1 (zh) 治疗多发性硬化的方法
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
MX9605072A (es) Dispositivo dispensador para pretratamiento.
ATE215084T1 (de) Imidazopyridin-azolidinone
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
GB9924941D0 (en) Treatment of dyskinesia
BR9915984A (pt) Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica
MX9603305A (es) Proceso mejorado para la ruptura de emulsiones de aceite.
WO2003039438A3 (de) Pna-konjugat zur therapie der chronischen myeloischen leukämie (cml)
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]